In the US there is an epidemic of childhood obesity. In the last 25 years, the prevalence of childhood obesity has tripled, and several clinical cases show that this condition causes serious health problems in children, especially cardiovascular disorders.
Hypercholesterolemia occurs when blood cholesterol levels are higher than what is considered normal. Among the factors that influence its increase are inadequate diets, liver, endocrine and renal diseases and familial hypercholesterolemia. If the recommended levels are exceeded, the chances of developing coronary diseases are increased.
The American Academy of Pediatrics recommends reducing the age to eight years to treat childhood obesity drugs, because the presence of cardiovascular problems at an early age is becoming very frequent. A recommendation not without controversy, which has raised controversy among experts, since primary prevention trials have shown a decrease in the rates of cardiovascular events, but not a decrease in mortality among adults.
The main negative consequence of excess cholesterol in the blood is the development of coronary diseases
With eight years of age, a child's brain and other organs remain in the developmental stages and, therefore, concern that long-term pharmacotherapy initiating it at this age may negatively impact the central nervous system, immune function, hormones, metabolism or other systems in an unforeseen way.
Thus, the great question that arises is whether they are willing to treat hypercholesterolemia associated with childhood obesity with a growing range of powerful drugs for adults, or focus on adopting measures such as food regulation, improving the quality of nutrition in school, promoting physical activity inside and outside the school environment, and providing greater funding for programs for the prevention and treatment of obesity.